New drug RC88 shows promise in early trial for Hard-to-Treat cancers
NCT ID NCT04175847
First seen Jan 10, 2026 · Last updated May 15, 2026 · Updated 14 times
Summary
This study tested an experimental drug called RC88 in 198 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the drug is safe and to find the best dose. Researchers also looked for early signs that the drug might shrink tumors or slow cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Drum Tower Hospital
Nanjing, Jiangsu, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
Conditions
Explore the condition pages connected to this study.